Michael Friedman
AbbVie (United States) · 37 works · 744 citations · h-index 8
Top works
- In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
- THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects
- Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Discovery of Selective and Orally Bioavailable Protein Kinase Cθ (PKCθ) Inhibitors from a Fragment Hit
- Covalent binders in drug discovery
- Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-α production
- Design and synthesis of tricyclic cores for kinase inhibition
- Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712
- Discovery of Orally Efficacious Bridged Piperazines as smTNF Modulators
- Fig. S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Table S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S2 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S2 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S4 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S10 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S10 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Covalent Inhibitors as Anti-Inflammatory Agents
- Fig. S1 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S5 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
- Fig. S4 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression